| Clinical study "common" name (formal title) | Number of enrollees (per protocol [PP]/intent-to-treat [ITT]) | Funding source (pharmaceutical company/National Institutes of Health [NIH]) | Year completed | Primary publication | Full study treatment protocol |
|---|---|---|---|---|---|
| BRILLIANCE (Ranibizumab vs Verteporfin Photodynamic Therapy in Asian Patients With Myopic Choroidal Neovascularization) | N=475 | Novartis (NCT01922102) | 42614 | Chen Y, et al. Ranibizumab versus verteporfin photodynamic therapy in Asian patients with myopic choroidal neovascularization: BRILLIANCE, a 12-month, randomized, double-masked study. Retina. 2019 Oct;39(10):1985-1994. https://journals.lww.com/retinajournal/Fulltext/2019/10000/RANIBIZUMAB_VERSUS_VERTEPORFIN_PHOTODYNAMIC.18.aspx |
|